Compare · Head-to-head
Angiotensin 1-7 vs Thymosin Alpha-1.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Angiotensin 1-7, then use the table to confirm fit.
Angiotensin 1-7 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
Angiotensin 1-7
Protective renin-angiotensin-system peptide studied for vascular, anti-inflammatory, and anti-fibrotic effects.
01 · At a glance
| Decision factor | Angiotensin 1-7 | Thymosin Alpha-1 |
|---|---|---|
| Primary fit | longevity & anti-aging and immune support comparisons | longevity & anti-aging and immune support comparisons |
| Evidence | Tier B | Tier B |
| Risk | low | medium |
| Experience level | advanced | intermediate |
| Budget tier | premium | mid |
| Administration route | intravenous, subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | Angiotensin 1-7 | Thymosin Alpha-1 |
|---|---|---|
| Goal fit | Longevity & Anti-Aging, Immune Support | Longevity & Anti-Aging, Immune Support |
| What users compare it for | Potential endothelial, anti-inflammatory, and anti-fibrotic benefits in vascular and pulmonary research settings. | Immune modulation; clinical literature broader than most RUO peptides. |
| Onset timeline | Hemodynamic effects can appear quickly during infusion; structural outcomes are studied over longer periods. | Immune biomarkers and clinical outcomes over weeks to months. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | Angiotensin 1-7 | Thymosin Alpha-1 |
|---|---|---|
| Adverse effects | Main practical risk is hypotension or reflex tachycardia, especially in combination with other RAAS-active therapies. | Generally tolerable in clinical contexts; clinician oversight required. |
| Contraindications | Avoid in hypotension, volume depletion, and use caution with ACE inhibitors or ARBs. | Potential interactions with immunotherapies/vaccines. |
| Interaction notes | Likely additive blood-pressure lowering with ACE inhibitors, ARBs, and other vasodilating strategies. | Potential interactions with immunotherapies/vaccines; do not provide combination advice. |
| Regulatory status | Investigational | Investigational |
| FDA flag | No current flag noted | FDA status unclear |
| WADA status | Not listed | Not listed |
04 · Age & monitoring
| Decision factor | Angiotensin 1-7 | Thymosin Alpha-1 |
|---|---|---|
| Supported age ranges | No age guidance yet | 35-44, 45-54, 55-64, 65+ |
| Life-stage note | Not yet documented | Age fit improves later in life because immune-support logic becomes more relevant as immunosenescence rises. |
| Monitoring burden | Not specified | medium |
| Follow-up cadence | Not yet documented | Periodic reassessment every few months, especially if health context is complex. |
05 · Cost & sourcing
| Decision factor | Angiotensin 1-7 | Thymosin Alpha-1 |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | $79.98 |
| Estimated monthly cost | No reliable estimate yet | $53.32 |
| Cost confidence | No estimate | High confidence |
06 · Before you buy
| Decision factor | Angiotensin 1-7 | Thymosin Alpha-1 |
|---|---|---|
| Tracked vendor listings | 0 listings | 1 listing |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Tracked product pages are available, which makes it easier to review the listing before you click out. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.